vTv Therapeutics (vTv Therapeutics) GF Score : 46/100 (As of Jun. 09, 2024)

View and export this data going back to 2015. Start your Free Trial

What is vTv Therapeutics GF Score?

vTv Therapeutics has the GF Score of 46, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 5/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 1/10
5. Momentum Rank : 6/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes vTv Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of vTv Therapeutics's GF Score

For the Biotechnology subindustry, vTv Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

vTv Therapeutics's GF Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, vTv Therapeutics's GF Score distribution charts can be found below:

* The bar in red indicates where vTv Therapeutics's GF Score falls into.

vTv Therapeutics (NAS:VTVT) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

vTv Therapeutics GF Score Related Terms

Thank you for viewing the detailed overview of vTv Therapeutics's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

vTv Therapeutics (vTv Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » vTv Therapeutics Inc (NAS:VTVT) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

5VT0:Germany

Address

3980 Premier Drive, Suite 310, High Point, NC, USA, 27265

Website

https://www.vtvtherapeutics.com

vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. The company lead program is TTP399, an orally administered, small molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes.

Executives

Steven L. Tuch	officer: Chief Financial Officer	C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
John A Fry	director	C/O DELAWARE INVESTMENTS, 2005 MARKET ST. 34TH FL., PHILADELPHIA PA 19103
Jonathan Isaacsohn	director	C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Paul J Sekhri	director, officer: President and CEO	C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
Fahed Al-marzooqi	director	AL KHATEM TOWER, ABU DHABI GLOBAL MARKET, ABU DHABI C0 00000
Keith R. Harris	director	C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016
Hersh Kozlov	director	WOLF BLOCK SCHORR & SOLIS, 1940 RTE 70 E, CHERRY HILL NJ 08003
Howard L. Weiner	director	4170 MENDENHALL OAKS PKWY, HIGH POINT NC 27265
Chandresh Harjivan	director	C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Al-nahyan Tahnoon Bin Zayed S.	10 percent owner	OFFICE 2458, FLOOR 24, AL-SILA TOWER, ABU DHABI C0 00000
G42 Investments Ai Holdings Rsc Ltd.	director, 10 percent owner	OFFICE 801, FLOOR 8, AL KHATEM TOWER, ABU DHABI C0 00000
Barry K. Brown	officer: Chief Accounting Officer	C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Rich S. Nelson	director, officer: Acting Chief Executive Officer	C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Ronald O Perelman	10 percent owner	35 EAST 62ND STREET, NEW YORK NY 10021
Deepa Prasad	director, officer: President and CEO	C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, SUITE 310, HIGH POINT NC 27265